Pharmaco - Press Releases

Date	Title	Company
01-Jun-2020	San Diego Top Doctor Collaborates with Therapeutic Solutions International to Report QuadraMune(TM) Immune Boosting Data in Clinical Trial	Therapeutic Solutions International, Inc.
01-Jun-2020	CytRx Corporation Highlights Orphazyme's Rolling Submission of its New Drug Application with the U.S. FDA for Arimoclomol in Niemann-Pick Disease Type-C	CytRx Corporation
01-Jun-2020	White Paper for Investors and Lenders Highlights Risks of Excess Assets in Biopharmaceutical Sector	Tiger Group
01-Jun-2020	Publication in Nature Communications Highlights the Preclinical Development of SYNB1891 and its Potential as a Dual Innate Immune Activator to Stimulate an Immune Response in Difficult to Treat Tumors	Synlogic, Inc.
01-Jun-2020	Henlius and Accord Receive Positive CHMP Opinion for Oncology Biosimilar, HLX02 (Trastuzumab)	Henlius
01-Jun-2020	AbbVie and Jacobio Announce Strategic Collaboration to Advance SHP2 Inhibitors	AbbVie
31-May-2020	Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT® (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics Announced the Results of the Phase 1b Clinical Study of TYVYT® (Sintilimab Injection) in Combination with IBI305 (Bevacizumab Biosimilar) in the Treatment of Advanced Hepatocellular Carcinoma	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics Announced the Long-Term Follow-Up Results of TYVYT(R) (Sintilimab Injection) in the Treatment of Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (Nasal Type)	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT(R) (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics Announced the Results of the Phase 1b Clinical Study of TYVYT(R) (Sintilimab Injection) in Combination with IBI305 (Bevacizumab Biosimilar) in the Treatment of Advanced Hepatocellular Carcinoma	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (Nasal Type)	Innovent Biologics, Inc.
31-May-2020	BioMarin Provides Highlights of 4 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A	BioMarin Pharmaceutical Inc.
31-May-2020	(ASCO2020) Ascentage Pharma Presents Latest Clinical Data of Apoptosis Targeting Drug Candidates, Showing Promising Clinical Effects with Combination Therapies	Ascentage Pharma
30-May-2020	MimiVax Phase 2 study of SurVaxM in combination with pembrolizumab opens for recurrent glioblastoma patients	MimiVax LLC
30-May-2020	Coronavirus (COVID-19) Update: Daily Roundup	U.S. Food and Drug Administration
29-May-2020	Mylan Invalidates Sanofi's Lantus® SoloSTAR® Device Patents in IPR Proceedings	Mylan N.V.
29-May-2020	Immunotherapy Drugs Market Worth $274.6 Billion by 2025 - Exclusive Report by MarketsandMarkets™	MarketsandMarkets